Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ellagic acid + pomegranate extract is a combination dietary supplement consisting of ellagic acid, a polyphenolic antioxidant, and pomegranate (Punica granatum) extract, which is standardized to contain high levels of ellagitannins and other polyphenols. Pomegranate extract is rich in punicalagin and other ellagitannins that are metabolized in the body to produce ellagic acid. This combination exhibits potent antioxidant, anti-inflammatory, and potential anticancer properties. Mechanistically, these compounds act by scavenging free radicals, modulating inflammatory pathways (such as NF-κB), downregulating pro-inflammatory cytokines (including iNOS and TNF-α), inhibiting matrix metalloproteinases involved in cancer metastasis (MMP-2/-9), suppressing STAT3 phosphorylation, and reducing oxidative stress. Clinical studies have explored their use for conditions such as prostate cancer, chronic colonic inflammation, asthma symptom relief, skin hyperpigmentation from UV exposure, and general antioxidant support[2][3][4][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ellagic acid + pomegranate extract.